Zycortal® (Dechra Veterinary Products) is indicated for replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism. Zycortal contains desoxycortone pivalate (DOCP) – an aldosterone analogue with purely mineralocorticoid effect. Zycortal is available as a prolonged-release suspension for subcutaneous injection and the dosing interval is approximately 25 days. The exact dose to be given and the interval between treatments depend on the dog’s clinical response as well as sodium and potassium levels. A glucocorticoid (. prednisolone) is also needed daily to replace the missing cortisol. To obtain a Monitoring and Dose Adjustment Flowchart, or for further advice, contact Dechra by e-mailing technical@.
Laboratory values can show increased urea ( BUN ), or increased blood creatinine in cases of uremic pericarditis . Generally however, laboratory values are normal, but if there is a concurrent myocardial infarction (heart attack) or great stress to the heart, laboratory values may show increased cardiac markers like Troponin (I, T), CK-MB , Myoglobin , and LDH 1 (Lactase Dehydrogenase isotype 1). The preferred initial diagnostic testing is the ECG which may show a 12-lead electrocardiogram with diffuse, non-specific, concave ("saddle-shaped"), ST segment-elevations all leads except aVR and V1  and PR segment-depression possible in any lead except aVR;  sinus tachycardia, and low-voltage QRS complexes can also be seen if there is subsymptomatic levels of pericardial effusion. The PR depression is often seen early in the process as the thin atria are affected more easily than the ventricles by the inflammatory process of the pericardium.